Supplementary Figures 1 - 8 from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Jannik N. Andersen, Thomas A. Paul et al.|Unknown|2023Cited by 0
Supplementary Methods, Figure Legends from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Jannik N. Andersen, Thomas A. Paul et al.|Unknown|2023Cited by 0
Supplementary Figures 1 - 8 from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Jannik N. Andersen, Thomas A. Paul et al.|Unknown|2023Cited by 0
Supplementary Methods, Figure Legends from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Jannik N. Andersen, Thomas A. Paul et al.|Unknown|2023Cited by 0
Data from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Jannik N. Andersen, Mike Peoples et al.|Unknown|2023Cited by 0